Agila's business model in specialties has, over the years, evolved from a joint-venture focus to adomain-led partnership model. We have joint ventures with US-based Sagent Pharmaceuticals, Inc., to jointly develop, supply and market injectable products for the U.S. market.

Our domain strategy of focusing on developing a comprehensive product portfolio in specific therapies has resulted in strategic partnerships with global pharma players like GlaxoSmithKline and Pfizer. In 2008, Strides entered into a licensing and supply agreement with GlaxoSmithKline for 95 emerging countries excluding Sub Saharan Africa and India.

In early 2010, Strides entered into a licensing and supply agreement with Pfizer for a portfolio of 40 off-patent sterile injectables and oral products (many of which are oncology therapeutics). The products will be commercialised through Pfizer's Established Products Business Unit to healthcare providers and patients in the USA. The agreement was further extended in mid 2010 with a licensing and supply agreement covering 38 generic oncology products for markets in the EU, Canada, Australia, New Zealand, Japan and Korea and additional products for the USA, in all a portfolio of 45 products.

The partnerships we have forged with the big pharmaceutical companies provide an opportunity for Strides to play a growingly important role in the global healthcare industry, and establish it as a partner of choice in the highly complex steriles segment.

Some of our partners include:

• Pfizer
• GlaxoSmithKline
• Sandoz
• Teva
• Novartis
• Aspen
• Martindale
• Sagent
• ICN
• Actavis